Given the potential of DoxFILN in tumor‐targeted and cell‐specific delivery of Dox‐Fn and membrane‐bound IL15c, we measured the efficacy of DoxFILN in priming anti‐tumor immunity. The gene discussed is FN1; the disease is neoplasm.